Roche News
Most Popular Roche Story
Infections and deaths force Biogen, Roche to suspend blockbuster program
In a significant setback, Biogen Idec and Roche have suspended the troubled development program of ocrelizumab for rheumatoid arthritis, and analysts are already questioning if work related to... Read more...
Latest Headlines
- March 19, 2010
- March 17, 2010
- February 11, 2010
- February 9, 2010
- February 3, 2010
- February 1, 2010
- February 1, 2010
- January 11, 2010
- January 11, 2010
- December 21, 2009
- December 11, 2009
- December 11, 2009
- December 10, 2009
- December 8, 2009
- December 7, 2009
- December 2, 2009
- November 30, 2009
- November 20, 2009
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
